Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
In this Phase 3 study (n=673), ultra-rapid lispro was non-inferior to standard lispro (as part of an optimised basal bolus regimen) for change from baseline in HbA1c at 26 weeks (mean change -0.38% v -0.43%; estimated treatment difference of 0.06% [95% CI -0.05 to 0.16]).
Source:
Diabetes Care
SPS commentary:
The ultra-rapid formulation of insulin lispro evaluated in this study (Lyumjev) contains citrate to increase local vascular permeability and treprostinil to induce local vasodilation to achieve accelerated absorption. It is now available in the UK for the treatment of type 1 and type 2 diabetes mellitus in adults.